Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4461 Target Snapshot

NAD-dependent protein deacetylase sirtuin-3, mitochondrial · SINGLE PROTEIN · Homo sapiens

1,022Compounds
272Assays
3Approved Drugs
603.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9NTG7. Use UniProt Q9NTG7 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NTG7 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NAD-dependent protein deacetylase sirtuin-3, mitochondrial as ChEMBL target CHEMBL4461, mapped to UniProt Q9NTG7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NAD-dependent protein deacetylase sirtuin-3, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4461
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9NTG7
NAD-dependent protein deacetylase sirtuin-3, mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether NAD-dependent protein deacetylase sirtuin-3, mitochondrial is the right protein anchor across sources, using UniProt Q9NTG7 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNAD-dependent protein deacetylase sirtuin-3, mitochondrial
UniProt AccessionQ9NTG7
Component TypeProtein
Sequence Length399 aa

NAD-dependent protein deacetylase sirtuin-3, mitochondrial

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as NAD-dependent protein deacetylase sirtuin-3, mitochondrial, mapped to UniProt Q9NTG7. Sequence length is 399 aa.

Mapped IDQ9NTG7
Review nameNAD-dependent protein deacetylase sirtuin-3, mitochondrial
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC50511.0
KI22.0
EC5037.0
KD33.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2332041 8.49 IC50 3.2 Preclinical
CHEMBL2332039 8.4 IC50 4.0 Preclinical
CHEMBL2332037 8.31 IC50 4.9 Preclinical
CHEMBL5614132 8.3 IC50 5.0 Preclinical
CHEMBL2338810 8.14 IC50 7.2 Preclinical
CHEMBL2332043 8.12 IC50 7.6 Preclinical
CHEMBL2332042 7.89 IC50 13.0 Preclinical
CHEMBL2332040 7.64 IC50 23.0 Preclinical
CHEMBL2332038 7.62 IC50 24.0 Preclinical
CHEMBL2338813 7.55 IC50 28.0 Preclinical
Distribution

pChEMBL Value Distribution

71
5.0
64
5.5
45
6.0
22
6.5
17
7.0
6
7.5
6
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAFFEINE
CHEMBL113
Approved 1948
Assay Landscape

Assay Landscape

272
Total Assays
322
Tested Compounds
3
Assay Types
Binding — 263 assays, 322 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 137 159 5.4
assay format 71 134 5.7
cell-based format 48 29 5.4
subcellular format 4 0
mitochondrion format 2 0
tissue-based format 1 0
Functional — 6 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 6 0
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 2 0
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine